文献速递神经核医学肿瘤 PET/CT

O-(2-[18F]氟乙基)-L-酪氨酸PET不同分析方法检测胶质母细胞瘤晚期假性进展的临床效用

Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PET.
PubMed 文献 · Clin Nucl Med · 2019-01-01

该回顾性研究纳入36例组织病理学确诊的胶质母细胞瘤患者,在放疗结束12周后疑似复发/进展时行18F-FET PET,采用5种肿瘤与正常脑参考区定义方法计算肿瘤/脑比值以鉴别晚期假性进展与真性复发。结果显示各方法AUC为0.80–0.88(均P<0.01),方法间分类差异无统计学意义(均P>0.05),提示18F-FET PET稳健但需方法学标准化。

要点

  • 18F-FET PET可可靠鉴别胶质母细胞瘤晚期假性进展与真性进展,AUC为0.80–0.88。
  • 5种分析方法间分类差异无统计学意义(均P>0.05),聚焦最高摄取体素的方法倾向更优。
  • 不同中心间需方法学标准化与协调以确保可比性。

核心结论

  • 无论采用何种分析方法,18F-FET PET均是检测胶质母细胞瘤晚期假性进展的稳健工具,方法间仅存微小差异。

研究设计与样本

  • 回顾性分析36例组织病理学确诊的胶质母细胞瘤患者,基于MRI和RANO标准在放疗停止12周后疑似复发/进展。
  • 采用5种肿瘤和正常脑参考区定义方法计算肿瘤/脑比值进行半定量分析,以组织病理学和/或临床影像随访为参考。

主要发现

  • 18F-FET PET鉴别假性进展与真性肿瘤进展的AUC范围为0.80至0.88(均P<0.01)。
  • 无论选择何种方法,各分析方法间分类差异无统计学意义(均P>0.05)。
  • 聚焦最高摄取体素的方法倾向表现更优。

关键数值与推荐

  • AUC范围为0.80至0.88(均P<0.01)。
  • 各方法间分类差异均P>0.05。
  • 疑似复发/进展定义为放疗停止后超过12周。

临床怎么用

  • 18F-FET PET可用于胶质母细胞瘤放疗后晚期疑似假性进展的鉴别诊断。
  • 分析方法选择对结果影响较小,但需注意方法学标准化与跨中心协调。

局限性

  • 回顾性研究设计。
  • 样本量36例。
  • 需方法学标准化与协调以确保不同中心间可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: PET/CT using O-(2-[F]fluoroethyl)-L-tyrosine (F-FET) has proven valuable in differentiating tumor recurrence and progression from therapy-induced changes. This study aimed to investigate the diagnostic performance of several analytic approaches in the setting of suspected late pseudoprogression (PsP) in glioblastoma multiforme (GBM). METHODS: Retrospective analysis of tumor recurrence was performed in 36 patients with histopathologically confirmed GBM and suspicion of recurrence/disease progression more than 12 weeks from cessation of irradiation based on MRI and Response Assessment in Neuro-Oncology working group criteria. For differentiation of late PsP from true tumor recurrence, images were analyzed semiquantitatively employing tumor-to-brain ratios using 5 different approaches for tumor and normal brain reference region definition, respectively. Histopathology and/or clinical and imaging follow-up served as reference. Respective areas under the receiver operating characteristic curve were compared. RESULTS: F-FET PET was able to reliably differentiate PsP from true tumor progression with areas under the receiver operating characteristic curve ranging from 0.80 to 0.88 (all P < 0.01). Irrespective of the approach chosen, the classification differences between the applied methods were not significant (all P > 0.05), albeit approaches focusing on voxels with the highest uptake tended to perform superior. CONCLUSIONS: Irrespective of the analytical approach, F-FET PET is a robust tool for detection of late PsP with only minor differences between different analytical approaches. However, methodological standardization and harmonization are needed to ensure comparability between different centers.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kertels O, Mihovilovic MI, Linsenmann T, et al. Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PET. Clin Nucl Med. 2019. PMID: 31274552. doi:10.1097/RLU.0000000000002652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。